共 66 条
[1]
Ayyar BV(2016)Coming-of-Age of Antibodies in Cancer Therapeutics Trends Pharmacol Sci 37 1009-1028
[2]
Arora S(2010)Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy Cancer Treat Rev 36 458-467
[3]
O’Kennedy R(2016)Novel immunotherapies in lymphoid malignancies Nat Rev Clin Oncol 13 25-40
[4]
Seimetz D(2018)Redirecting T cells to hematological malignancies with bispecific antibodies Blood 131 30-38
[5]
Lindhofer H(2009)Bispecific T-cell engaging antibodies for cancer therapy Cancer Res 69 4941-4944
[6]
Bokemeyer C(2017)Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL) Ann Oncol 28 2009-2012
[7]
Batlevi CL(2018)T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics Pharmacol Ther 182 161-175
[8]
Matsuki E(2007)Two heads are better than one Nat Biotechnol 25 1233-1234
[9]
Brentjens RJ(2018)Next generation antibody drugs: pursuit of the “high-hanging fruit” Nat Rev Drug Discov 17 197-223
[10]
Velasquez MP(2005)BiTEs: bispecific antibody constructs with unique anti-tumor activity Drug Discov Today 10 1237-1244